China Literature funded 100 short dramas from its novel catalogue

What was announced or recorded

On 18 March 2024, China Literature Limited (HKEX: 0772), the Tencent-backed web-novel and publishing group, presented its 2023 annual results. Under a section on IP commercialisation, the company states it has 'entered the short drama segment' through a 'Short Drama Star Incubation Plan', backed by a creative fund of more than RMB100 million and supporting more than 100 short-drama series, and says it pioneered an 'interactive short drama' format. It adds that several of those series had already surpassed RMB10 million each in gross revenue.

What the documents establish

The disclosure sits inside a section on IP commercialisation and monetisation alongside merchandise licensing and game adaptations of the company's fiction catalogue, framing short drama as another channel for adapting existing licensed intellectual property rather than a stand-alone content business. Total 2023 group revenue was RMB7.0 billion, of which 'IP operations and others', the segment that would carry adaptation-based income, contributed RMB3.1 billion; the results do not break short-drama revenue out of that segment separately. The company's interim 2023 results, presented five months earlier on 10 August 2023, make no mention of short dramas at all, corroborating that the incubation plan and its fund were new to the year-end disclosure.

Announced versus delivered

A year later the picture firms up. China Literature's 2024 annual results, presented 18 March 2025, report under a 'Short Dramas' heading that the company launched more than 100 titles during 2024, with its top-performing title generating 'nearly RMB40 million' in gross revenue, roughly four times the RMB10 million-plus threshold cited for 2023's leading titles. That is a genuine year-on-year comparison the company itself supplies, though it remains a figure for one title rather than a segment total.

What to watch

This is an editorial caution rather than a stated limit: the fund size and title count are cumulative programme figures, not annual spend, so reusing them without a stated period risks implying an annual rate the filings do not state.

• Is a cited RMB100 million fund or 100-plus title count being treated as cumulative-to-date, or wrongly as an annual figure?
• Does the short drama in question adapt a title from China Literature's own licensed catalogue, the mechanism the company describes, or was it commissioned independently?
• Has China Literature disclosed a short-drama revenue figure separate from its combined 'IP operations and others' segment in any later filing?

The two annual results, read together, show a publisher moving from announcing an incubation programme to reporting a specific hit title's revenue within twelve months, real progression, though still told through top titles rather than a segment-wide account.